Leonard Schleifer

The New York–based biotech Schleifer founded in 1988 has been much in the news this year for the drug, an antibody cocktail, it developed to fight COVID-19—and which was used in October to treat President Trump. The FDA granted the drug an emergency use authorization in late November. Regeneron also recently won FDA approval for Inmazeb, another antibody cocktail and the first-ever drug proved to be effective in treating Ebola. Those innovations have helped boost Regeneron’s stock—its total return over the past 12 months is 51%—and the biotech’s impressive financial results support the investor enthusiasm: Revenues and profits are up 40% and 47% respectively for the past 12 months, largely because of strong sales of drugs that treat macular degeneration and allergic diseases like eczema.